Integrated Strategy for Hit-to-Lead Optimization: The ‘DOTS’ approach

webinar

Thu, 27 Oct 2022, 16:00 CEST (Berlin)

Dr. Xavier Morelli, Centre de Recherche en Cancérologie de Marseille (CRCM), France

Integrated Strategy for Hit-to-Lead Optimization: The ‘DOTS’ approach

In recent decades, the identification of hits has been greatly facilitated by advances in high throughput screening (HTS) and the design of chemical libraries. It would be wishful to optimize the automation of the ‘hit-to-lead’ (H2L) process. Xavier will present an integrated strategy for the H2L optimization phase and the automated design of chemical probes called Diversity Oriented Target-Focused Synthesis (DOTS and CovaDOTS) approach.
In the ‘DOTS’ approach, a focused virtual library is generated by combining an activated fragment — corresponding to a substructure that binds to a target — with a collection of functionalized chemical blocks, using in silico encoded relevant chemical reactions. Target-specific compounds are selected by virtual screening, followed by in vitro synthesis and evaluation using a robotic platform. The proof of concept was successfully completed by the optimization of bromodomain inhibitors that lead to the validation of several compounds with an affinity that had improved by several orders of magnitude. The proposed process can be implemented in academic environments or biotechnology companies that desire an automation of these processes.

 

Register and tune in for a very exciting webinar.

1 Hoffer L. et al. J. Med. Chem. 2018 Jul 12;61(13):5719-5732; Carrasco K. et al., J. Med. Chem. 2022 Apr 14;65(7):5660-5674 

2 Hoffer L., et al. J. Chem. Inf. Model. 2019 2019 Apr 22;59(4):1472-1485

Current news

category
Events
Announcing BioSolveIT's DrugSpace Symposium 2025: Bridging Science
June 26, 2025 09:43 CEST
We are pleased to announce the fourth edition of the BioSolveIT DrugSpace Symposium, taking place on September 24–25, 2025. This year’s theme, “Bridging Science,” highlights the growing importance of interdisciplinary collaboration in driving innovation across the drug discovery landscape. As the field evolves, it becomes increasingly clear that real progress...
Read on
Psst... Are You Following Us Yet? Follow the Science (and a Bit More)
June 25, 2025 08:44 CEST
There’s a lot going on behind the scenes—ideas taking shape, tools evolving, science in motion. And while the website tells you what our software does, our social media gives you a look at how it lives. We’re active on LinkedIn, BlueSky, and YouTube, sharing everything from scientific snapshots to educational...
Read on
AMBrosia Just Got Bigger: 126 Billion Compound Update Now Available
June 11, 2025 13:21 CEST
We are thrilled to announce a major update to the AMBrosia Chemical Space in collaboration with Ambinter! The state-of-the-art source for diverse drug-like scaffolds now boasts an incredible 126 billion of synthetically accessible compounds for drug discovery projects. What does the update feature? Expanded to an astounding 125,924,571,692 compounds (1.26...
Read on